Oropharyngeal carcinoma is a malignant neoplasm arising from the mucosal epithelium of the oropharynx, including the base of tongue, tonsils, soft palate, and posterior pharyngeal wall, frequently associated with HPV infection or tobacco and alcohol use.

Oropharyngeal Carcinoma

2. Epidemiology

3. Anatomy and Function

Understanding the anatomy is crucial — it determines the clinical features, patterns of spread, and surgical approach.

The oropharynx extends vertically from the soft palate to the superior surface of the hyoid bone (floor of the vallecula) ^[2]. It is laterally bounded by the pharyngeal constrictor muscles and the medial aspect of the mandible ^[2].

Boundary	Landmark
Superior	Soft palate (junction with nasopharynx)
Inferior	Superior surface of hyoid bone / plane of vallecula (junction with hypopharynx/supraglottic larynx)
Anterior	Anterior tonsillar pillars (palatoglossal arch), circumvallate papillae of tongue
Posterior	Posterior pharyngeal wall (overlying prevertebral fascia)
Lateral	Palatine tonsils, pharyngeal constrictors, medial mandible

The components are: tonsillar region, base of tongue, soft palate, and posterolateral pharyngeal wall ^[2]^[3].

Sub-site	Key Features
Tonsil (commonest) ^[3]	Palatine tonsils sit in the tonsillar fossa between anterior (palatoglossal) and posterior (palatopharyngeal) pillars. Rich lymphoid tissue — Waldeyer's ring component. Most common sub-site for oropharyngeal SCC.
Tongue base ^[3]	Posterior one-third of tongue, behind circumvallate papillae. Contains lingual tonsils. Tumours here are often large at presentation because the tongue base is difficult to visualise on routine oral examination.
Soft palate ^[3]	Muscular extension of hard palate. Minor salivary glands are abundant here — hence minor salivary gland tumours can present as submucosal masses.
Posterior pharyngeal wall ^[3]	Mucosal lining overlying superior and middle pharyngeal constrictors and prevertebral fascia.

4. Etiology and Risk Factors

4.2 Human Papillomavirus (HPV) Infection

HPV is the key aetiological factor for oropharyngeal carcinoma ^[1]^[4].

HPV type 16 and 18 (high-risk serotypes) — HPV-16 accounts for ~90% of HPV-positive oropharyngeal SCC ^[2]
HPV-associated H&N cancer occur primarily in the oropharynx including tonsils and the base of tongue ^[2] — Why the oropharynx specifically? The tonsillar crypts have a specialised reticulated epithelium that lacks a complete basement membrane, allowing HPV to access basal cells more easily. This is analogous to the transformation zone of the uterine cervix.

Presents in young male patients who have a higher lifetime number of sexual partners and oral sex ^[2]^[4].

HPV-positive oropharyngeal SCC defines a distinct subset of patients compared with HPV-negative tobacco/alcohol-driven oropharynx cancer with the following features ^[2]:

Frequent LN metastasis — often presenting with a cystic neck node (because HPV-positive tumours in the tonsil/tongue base can be small primaries with large nodal disease)
Higher response rate to induction chemotherapy
Better prognosis — ~80% 5-year survival vs ~50% for HPV-negative
Deintensification of treatment can be considered while obtaining the same locoregional and overall survival seen with standard treatment options ^[2] — this is a major area of ongoing clinical trials (reducing radiation dose or omitting chemotherapy to reduce long-term toxicity)

HPV-Positive vs HPV-Negative OPC

Feature	HPV-Positive	HPV-Negative
Age	Younger (40–60)	Older ( > 60)
Sex	Male predominance	Male predominance
Risk factors	Oral sex, multiple partners	Smoking, alcohol
Typical sub-site	Tonsil, tongue base	Any oropharyngeal sub-site
p53	Wild-type (degraded by E6)	Mutated
p16 overexpression	Yes (surrogate marker)	No
Nodal metastasis	Frequent, often cystic	Less frequent at early stage
Prognosis	Excellent	Poorer
Treatment	De-intensification being studied	Standard full-dose CRT

5. Pathophysiology

5.5 Patterns of Metastasis

6. Classification

Histology	Proportion	Key Features
Squamous cell carcinoma	~90%	Most common; HPV-positive and HPV-negative subtypes
Lymphoma	Variable	Tonsils/tongue base are common extranodal sites; NHL > HL
Minor salivary gland tumours	Rare	May present as submucosal masses in the tongue base and soft palate ^[2]; includes adenoid cystic carcinoma, mucoepidermoid carcinoma
Others	Rare	Melanoma, sarcoma

T staging (same for both HPV+ and HPV-):

T Stage	Definition
T1	Tumour ≤ 2 cm
T2	Tumour > 2 cm but ≤ 4 cm
T3	Tumour > 4 cm OR extension to lingual surface of epiglottis
T4a	Tumour invades larynx, extrinsic tongue muscles, medial pterygoid, hard palate, or mandible
T4b	Tumour invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base, or encases carotid artery

N staging — HPV-positive (p16+) — CLINICAL:

N Stage	Definition
N0	No regional LN metastasis
N1	Unilateral LN(s), all ≤ 6 cm
N2	Bilateral or contralateral LN(s), all ≤ 6 cm
N3	LN(s) > 6 cm

N staging — HPV-negative (same as general H&N):

N Stage	Definition
N0	No regional LN metastasis
N1	Single ipsilateral LN ≤ 3 cm, no extranodal extension (ENE)
N2a	Single ipsilateral LN > 3 cm but ≤ 6 cm, no ENE
N2b	Multiple ipsilateral LN(s), none > 6 cm, no ENE
N2c	Bilateral or contralateral LN(s), none > 6 cm, no ENE
N3a	LN > 6 cm, no ENE
N3b	Any LN with clinical ENE

Notice that ENE (extranodal extension) is incorporated into N staging for HPV-negative but NOT for HPV-positive (clinical). This simplification for HPV-positive reflects the fact that even with nodal disease, outcomes remain good.

Overall Stage Grouping — HPV-positive:

Stage	T	N	M
I	T0-T2	N0-N1	M0
II	T0-T2	N2	M0
II	T3	N0-N2	M0
III	T0-T3	N3	M0
III	T4	Any N	M0
IV	Any T	Any N	M1

Compare with HPV-negative where stage IVA/IVB exist — HPV-positive maxes out at Stage III for M0 disease, reflecting the better prognosis.

High Yield: AJCC 8th Edition Key Change

Oropharyngeal SCC is staged differently based on p16/HPV status. HPV-positive tumours are "down-staged" compared to HPV-negative because of their better prognosis. A p16-positive patient with bilateral 5 cm nodes (N2) is only Stage II, whereas a p16-negative patient with the same finding might be Stage IVA.

7. Clinical Features

The clinical presentation depends on the sub-site and stage of disease. Many patients present late because early oropharyngeal tumours are asymptomatic or cause vague symptoms.

Symptom	Pathophysiological Basis
Sore throat ^[3]	Mucosal ulceration/inflammation from tumour invasion stimulates nociceptors in the pharyngeal mucosa supplied by CN IX and X
Referred otalgia ^[2]^[3]	Referred otalgia mediated by tympanic branches of CN IX and CN X ^[2] — the glossopharyngeal nerve (Jacobson's nerve) and vagus nerve (Arnold's nerve) share central connections with ear sensation in the nucleus of the tractus solitarius. Pharyngeal pain is "referred" to the ear because the brain misinterprets the signal's origin. This is a red-flag symptom.
Dysphagia and odynophagia ^[2]^[3]	Tumour mass obstructs the oropharyngeal lumen and/or infiltrates the muscles of swallowing (pharyngeal constrictors, tongue base). Ulcerated tumour surface causes pain on swallowing (odynophagia).
Muffled speech / "hot-potato" voice ^[2]^[3]	Muffled voice is seen with large tongue base tumours ^[2] — the tongue base is critical for articulation and resonance. A bulky tumour restricts tongue movement, altering the oral resonance chamber. The voice sounds as if the patient is speaking with a hot potato in their mouth.
Weight loss	A combination of: (1) reduced oral intake from dysphagia/odynophagia, (2) tumour-related cachexia mediated by cytokines (TNF-α, IL-6), and (3) increased metabolic demand. Constitutional symptom ^[2].
Haemoptysis/blood-stained saliva	Ulcerated, friable tumour surface bleeds — especially with trauma from food bolus passage.
Globus sensation	Early tumours or submucosal masses can produce a sensation of a lump in the throat.
Risk factor history	Smoking, alcohol, oral sex (HPV related) — always ask specifically ^[3]

Sign	Pathophysiological Basis
Mass / ulcer ^[3]	Direct visualisation of the tumour — may appear as an exophytic (outward-growing) mass, an ulcerated lesion with raised/rolled edges (typical of SCC), or a submucosal swelling (salivary gland tumour/lymphoma).
Asymmetrical tonsil ^[3]	Unilateral tonsillar enlargement or ulceration ^[2] — the most common presentation of tonsillar SCC. One tonsil looks significantly larger than the other, or has an irregular surface/ulcer. In adults, asymmetric tonsils should raise suspicion for malignancy.
Trismus ^[2]^[3]	Indicates advanced disease and usually results from involvement of pterygoid musculature ^[2]. The medial pterygoid muscle (a jaw closer) is infiltrated by tumour → muscle spasm and fibrosis → inability to open the mouth fully. Trismus indicates T4a disease (invasion of medial pterygoid).
Cervical lymphadenopathy (50%) ^[2]^[3]	Ipsilateral or bilateral non-tender cervical lymphadenopathy is a common presenting sign since the incidence of regional metastasis from oropharyngeal cancer is high ^[2]. Nodes are typically firm, non-tender, and fixed. In HPV-positive disease, nodes may be cystic (due to tumour necrosis within the node).
Tongue deviation	Invasion of CN XII (hypoglossal nerve) by locally extensive tumours → denervation of ipsilateral tongue muscles → tongue deviates toward the side of the lesion (because the contralateral genioglossus pushes the tongue toward the weak side).
Tongue paraesthesia	Invasion of lingual nerve (CN V3) → numbness/tingling of ipsilateral tongue.
Cranial nerve palsies	Advanced disease with parapharyngeal space/skull base invasion can affect CN IX, X, XI, XII.
Neck mass as presenting complaint	In HPV-positive oropharyngeal SCC, the primary tumour may be very small (even occult) but the neck node is the presenting complaint. A cystic Level II neck mass in a middle-aged adult is HPV-positive oropharyngeal SCC until proven otherwise.

Red Flags for Oropharyngeal Carcinoma

Any adult with persistent unilateral sore throat > 3 weeks, referred otalgia with normal otoscopy, unilateral tonsillar enlargement, or cervical lymphadenopathy should be investigated for oropharyngeal carcinoma. These are exam favourites.

Sub-site	Typical Presentation
Tonsil	Unilateral tonsillar enlargement/ulcer, sore throat, referred otalgia, neck mass
Tongue base	Dysphagia, "hot-potato" voice, referred otalgia, neck mass (often the first symptom — primary may be occult)
Soft palate	Visible mass/ulcer on soft palate, nasal regurgitation if palatal function compromised, altered speech
Posterior pharyngeal wall	Dysphagia, sore throat, may present late

Differential	Distinguishing Features
Minor salivary gland tumour ^[2]	May present as submucosal masses in the tongue base and soft palate — smooth, non-ulcerated, firm
Lymphoma ^[2]	Tonsils and tongue base may be the presenting site for a lymphoma — typically diffuse enlargement without ulceration; may have B symptoms
Peritonsillar abscess (quinsy)	Acute onset, fever, trismus, "hot-potato" voice, uvula deviation — responds to drainage/antibiotics
Tonsillar hypertrophy	Bilateral, symmetric, smooth — usually in children/adolescents
Benign salivary gland tumour (pleomorphic adenoma)	Submucosal, smooth, slow-growing
Deep neck space infection	Acute, fever, odynophagia, swelling — systemic signs

High Yield Summary

Definition: Malignant neoplasm of the oropharynx (tonsil, tongue base, soft palate, posterior pharyngeal wall); >90% SCC.

Epidemiology: Male predominance; bimodal age (younger HPV+, older HPV-); rising HPV-positive incidence globally.

Anatomy: Oropharynx extends from soft palate to hyoid bone. Tonsil is commonest sub-site. Rich lymphatic drainage → 50% have nodal metastasis at presentation. Level II nodes most commonly involved. Bilateral nodal disease common from midline structures (tongue base, soft palate).

Aetiology: HPV (type 16/18) is the key driver for oropharyngeal SCC — E6 degrades p53, E7 inactivates Rb. Smoking is the primary overall risk factor. Alcohol is synergistic with smoking. "5 S's": Smoking, Spirits, Sharp teeth, Sex, Spicy food.

HPV-positive vs HPV-negative: HPV+ = younger, better prognosis, p16 overexpression, wild-type p53, cystic nodal metastasis, de-intensification being studied. HPV- = older, smoking/alcohol, mutated p53, worse prognosis.

Field cancerisation: Chronic carcinogen exposure → entire mucosa at risk → synchronous/metachronous tumours → always do panendoscopy (laryngoscopy + bronchoscopy + OGD).

Premalignant lesions: Erythroplakia (highest single-lesion malignant potential) > Speckled leukoplakia (highest transformation rate) > Leukoplakia.

Clinical features: Sore throat, referred otalgia (CN IX/X), dysphagia/odynophagia, "hot-potato" voice, weight loss. Signs: mass/ulcer, asymmetric tonsil, trismus (pterygoid invasion = advanced), cervical lymphadenopathy (50%), tongue deviation (CN XII invasion).

AJCC 8th Edition: Separate staging for p16+ and p16- oropharyngeal SCC. HPV-positive tumours are "down-staged" reflecting better prognosis.

Active Recall - Oropharyngeal Carcinoma (Definition to Clinical Features)

Differential Diagnosis of Oropharyngeal Masses / Lesions

When a patient presents with an oropharyngeal mass, ulcer, dysphagia, or cervical lymphadenopathy, you need a structured differential diagnosis. The key is to think anatomically (what tissues exist in the oropharynx?) and then match each tissue of origin to its possible neoplastic, infective, or inflammatory pathology.

Structured Differential Diagnosis

Diagnosis	Tissue of Origin	Key Distinguishing Features	Why It Mimics Oropharyngeal SCC
Squamous cell carcinoma (SCC)	Surface epithelium	Most common (~90%); ulcerated or exophytic mass; risk factors (smoking, alcohol, HPV); p16/HPV testing distinguishes HPV+ from HPV-	— This IS the most common diagnosis
Lymphoma ^[2]^[3]	Lymphoid tissue (tonsils, tongue base)	Tonsils and tongue base may be the presenting site for a lymphoma ^[2]; typically diffuse, bulky, non-ulcerated enlargement; may have B symptoms (fever, night sweats, weight loss); often bilateral	Presents as tonsillar enlargement or tongue base mass — identical location to SCC. But lymphoma tends to produce smooth, fleshy, diffuse enlargement rather than ulceration. Biopsy is essential — you cannot distinguish them on appearance alone.
Minor salivary gland tumours ^[2]^[3]	Submucosal minor salivary glands	May present as submucosal masses in the tongue base and soft palate ^[2]; smooth, intact overlying mucosa (submucosal = pushing up from below, not ulcerating through the surface); includes adenoid cystic carcinoma (perineural invasion — pain/numbness), mucoepidermoid carcinoma, polymorphous adenocarcinoma	The mass is deep and covered by normal mucosa — unlike SCC which disrupts the surface. But advanced salivary gland malignancies can ulcerate, blurring the distinction.
Nasopharyngeal carcinoma (NPC) extending inferiorly	Nasopharyngeal epithelium	Endemic in Southern China/Hong Kong; EBV-driven; may extend from nasopharynx into oropharynx; bilateral cervical lymphadenopathy; cranial nerve palsies; EBV VCA IgA positive ^[5]	When NPC extends inferiorly, it can involve the soft palate and posterior pharyngeal wall, mimicking a primary oropharyngeal tumour. Nasoendoscopy reveals the primary in the nasopharynx (fossa of Rosenmüller).
Metastatic carcinoma to cervical nodes	Various primaries	A neck mass may be the presenting feature of an occult oropharyngeal primary; or it could represent metastasis from thyroid, lung, or other sites	The key question when you find a Level II neck node is: where is the primary? Always examine the oropharynx, particularly tonsil and tongue base.
Other rare malignancies	Various	Mucosal melanoma, sarcoma (rhabdomyosarcoma in children, leiomyosarcoma), neuroendocrine carcinoma	Very rare; melanoma may be pigmented or amelanotic; sarcomas present as submucosal masses

Exam Trap: Lymphoma vs SCC

A common mistake is to assume every tonsillar mass is SCC. Lymphoma — particularly diffuse large B-cell lymphoma (DLBCL) and extranodal marginal zone lymphoma — frequently presents in the tonsil or tongue base. If you see a large, smooth, fleshy tonsillar mass without ulceration, lymphoma should be high on your differential. Biopsy with flow cytometry and immunohistochemistry is essential — FNA alone does NOT provide material for tissue architecture or immunohistochemical analysis ^[6], so if lymphoma is suspected, excisional biopsy (e.g. tonsillectomy) or core needle biopsy is needed for subtyping.

Diagnosis	Key Features	Why It Enters the Differential
Pleomorphic adenoma of minor salivary gland	Most common benign salivary tumour; well-circumscribed, slow-growing, submucosal mass; usually painless; most commonly in soft palate	Submucosal mass in the palate or tongue base — could be mistaken for a malignant salivary gland tumour or early SCC
Papilloma	Benign epithelial neoplasm; pedunculated, finger-like projections; HPV 6/11 (low-risk types); usually small, painless	Exophytic mass that could be confused with verrucous carcinoma or early SCC
Haemangioma / vascular malformation	Bluish, compressible, non-tender; may bleed	A blue-tinged submucosal mass in the tongue base
Granular cell tumour	Firm, submucosal nodule; tongue is the most common oral site; benign in most cases	Can mimic a malignant submucosal lesion

Diagnosis	Key Features	Why It Mimics Oropharyngeal Carcinoma
Peritonsillar abscess (quinsy)	Acute onset; unilateral; fever, severe sore throat, trismus, "hot-potato" voice, uvula deviation to contralateral side; responds to drainage and antibiotics	Shares symptoms with oropharyngeal SCC: sore throat, trismus, muffled voice, unilateral tonsillar swelling. But quinsy is acute (days) vs carcinoma which is chronic (weeks-months). Absence of systemic infection signs and indolent course favours malignancy.
Deep neck space infection (parapharyngeal / retropharyngeal abscess)	Fever, toxaemia, neck swelling, odynophagia, dysphagia; CT shows rim-enhancing collection	Can present with similar pharyngeal symptoms; but systemic toxicity and acute onset distinguish it
Infectious mononucleosis (EBV pharyngitis)	Bilateral tonsillar enlargement with exudate; fever, lymphadenopathy, splenomegaly; positive Monospot; young patients	Bilateral tonsillar enlargement with cervical nodes in a young patient — but bilateral, acute, and systemic features point away from carcinoma
Chronic tonsillitis / tonsillar hypertrophy	Recurrent sore throats; bilateral; tonsillar crypts with debris (tonsilloliths); no ulceration	Bilateral and symmetric = benign. Unilateral and asymmetric = worry about malignancy.
Pharyngeal tuberculosis	Rare; granulomatous ulceration of pharynx; may present as chronic sore throat and dysphagia; associated with pulmonary TB; AFB on biopsy	Chronic ulcerated pharyngeal lesion — can look identical to SCC on examination. Must biopsy to differentiate. Important in Hong Kong where TB remains relevant.
Syphilitic chancre / gumma	Primary chancre: painless ulcer; tertiary gumma: destructive granulomatous lesion; both can involve oropharynx	Painless oropharyngeal ulcer — mimics early SCC. Sexual history and serology help.

Condition	Malignant Potential	Key Features
Erythroplakia	~50% harbour carcinoma in situ or invasive SCC at biopsy	Bright red mucosal plaque; cannot be attributed to any other diagnosis; highest single-lesion malignant potential
Leukoplakia	~5% transform over 10 years	White patch that cannot be scraped off; floor of mouth = highest risk site
Speckled leukoplakia	Highest transformation rate	Mixed red-white lesion; combines features of both erythroplakia and leukoplakia

Since 50% of oropharyngeal carcinoma patients present with cervical lymphadenopathy ^[2]^[3], the differential of a Level II neck mass is critical:

Diagnosis	Key Distinguishing Features
Metastatic oropharyngeal SCC	Firm, non-tender, fixed; Level II most common; may be cystic (HPV+); p16/HPV testing on FNA
Lymphoma	Rubbery, non-tender; may be multiple; bilateral; B symptoms; flow cytometry on FNA/biopsy
Reactive lymphadenopathy	Tender, mobile; associated recent URTI or dental infection; resolves with treatment
Branchial cleft cyst	Anterior to SCM, smooth, cystic; classically in young adults — but a "branchial cyst" in a patient > 40 is malignancy until proven otherwise
Tuberculous lymphadenitis (scrofula)	Matted nodes, cold abscess; chronic; relevant in Hong Kong endemic setting; AFB/PCR on aspirate
Salivary gland tumour (parotid tail / submandibular)	Location specific to the gland; FNA diagnostic
Carotid body tumour (paraganglioma)	Pulsatile mass at carotid bifurcation; splays carotid vessels on imaging; mobile side-to-side but not up-and-down

Feature	SCC	Lymphoma	Minor Salivary Gland Tumour	Peritonsillar Abscess
Onset	Weeks-months	Weeks-months	Months-years	Days
Surface	Ulcerated, irregular	Smooth, fleshy, intact mucosa	Smooth, submucosal, intact mucosa	Swollen, erythematous, bulging
Laterality	Usually unilateral	Often bilateral or diffuse	Unilateral	Unilateral
Pain	Late (nerve invasion)	Usually painless	Usually painless	Severe
Trismus	Indicates pterygoid invasion (advanced SCC)	Rare	Rare	Common (inflammation of pterygoids)
Fever	Absent (unless superinfected)	May have B symptoms	Absent	High-grade
Cervical nodes	Firm, non-tender, fixed	Rubbery, multiple	Uncommon early	Reactive, tender
Risk factors	Smoking, alcohol, HPV, age > 40	None specific; may have immunosuppression	None specific	Recent URTI, poor dentition
Investigation	Panendoscopy + biopsy ^[4]; FNA with p16/HPV ^[6]	Excisional biopsy / core biopsy for subtyping	Biopsy (often needs incisional/excisional)	CT neck; I&D if abscess confirmed

Golden Rule: Asymmetric Tonsils in Adults

Any unilateral tonsillar enlargement in an adult that persists for > 3 weeks without signs of acute infection mandates biopsy to rule out SCC or lymphoma. Do not simply observe — the consequences of delayed diagnosis are severe.

Important: The 'Lateral Neck Cyst' Trap

A cystic Level II neck mass in a patient over 40 years old should NEVER be dismissed as a branchial cleft cyst. This is a classic HPV-positive oropharyngeal SCC with cystic nodal metastasis until proven otherwise. FNA with cytology + p16 immunohistochemistry is mandatory. The primary tumour may be tiny or even occult — thorough oropharyngeal examination (including tongue base palpation and flexible nasendoscopy) is essential.

Why can lymphoma present at the tonsil and tongue base? The palatine tonsils and lingual tonsils are part of Waldeyer's ring — a ring of mucosa-associated lymphoid tissue (MALT) at the entrance to the aerodigestive tract. This is dense lymphoid tissue designed to sample antigens from inhaled/ingested material. Because lymphoma is a malignancy of lymphoid cells, any site with concentrated lymphoid tissue is a potential site for lymphoma. The tonsil is, in fact, one of the most common extranodal sites for non-Hodgkin lymphoma (particularly DLBCL).

Why do minor salivary gland tumours present submucosally? Minor salivary glands are embedded within the submucosa throughout the oral cavity and oropharynx (highest density in the soft palate, tongue base, and buccal mucosa). Tumours arising from these glands grow within the submucosal layer, pushing the overlying mucosa upward but not initially breaking through it. This is why they present as smooth, non-ulcerated bumps — the mucosa is stretched but intact. SCC, by contrast, arises from the surface epithelium and disrupts it from the outset.

Why does peritonsillar abscess mimic oropharyngeal SCC? Both cause unilateral tonsillar region swelling, trismus, muffled voice, and dysphagia. The mechanism of trismus differs though:

In abscess: inflammation and oedema in the peritonsillar space directly irritates the adjacent medial pterygoid muscle → reflex spasm
In SCC: direct tumour invasion into the medial pterygoid → fibrosis and mechanical restriction The tempo is the key differentiator — abscess develops over days with fever; carcinoma develops over weeks-months without fever.

High Yield Summary

Differential Diagnosis of Oropharyngeal Masses — The Big Three:

SCC (~90%) — ulcerated, exophytic, risk factors (smoking/alcohol/HPV), p16 testing essential
Lymphoma — smooth, fleshy tonsillar/tongue base mass; tonsils and tongue base may be the presenting site for lymphoma; need tissue biopsy for subtyping
Minor salivary gland tumour — submucosal masses in tongue base and soft palate; smooth, intact mucosa

Infective mimics: Peritonsillar abscess (acute onset, fever, unilateral, trismus), deep neck space infection, TB pharyngitis

Neck mass differential: A cystic Level II mass in a patient > 40 = metastatic HPV+ oropharyngeal SCC until proven otherwise. Never call it a "branchial cleft cyst" without ruling out malignancy.

Key differentiating questions:

Acute vs chronic onset?
Unilateral vs bilateral?
Ulcerated surface vs smooth/submucosal?
Risk factors present?
B symptoms?

Always biopsy — clinical appearance alone cannot distinguish SCC from lymphoma or minor salivary gland tumours. Panendoscopy + biopsy is mandatory; 10% risk of synchronous/metachronous tumour (field cancerisation) ^[4].

Active Recall - Differential Diagnosis of Oropharyngeal Carcinoma

References

^[2] Senior notes: felixlai.md (CA Oropharynx sections — differential diagnosis, patterns of metastasis, overview) ^[3] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p36 — oropharyngeal malignancy sub-sites and histology) ^[4] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p42 — workup and investigation, field cancerisation 10% synchronous/metachronous risk) ^[5] Senior notes: felixlai.md (Nasopharyngeal cancer — NPC overview and etiology) ^[6] Senior notes: felixlai.md (Pathological tests — FNA limitations, biopsy for lymphoma subtyping)

Diagnostic Criteria, Algorithm and Investigations for Oropharyngeal Carcinoma

Unlike some conditions with formal diagnostic criteria (e.g., Duke's criteria for infective endocarditis), oropharyngeal carcinoma is diagnosed through a combination of clinical assessment + tissue biopsy (histopathological confirmation) + staging investigations. There is no single blood test or score that clinches the diagnosis. The diagnosis is fundamentally histological — you must obtain tissue.

The key elements required for a complete diagnosis are:

Component	What It Answers	How It Is Obtained
1. Histological confirmation	Is it cancer? What type?	Panendoscopy + biopsy ^[4] or tonsillectomy / EUA + Bx ^[4]
2. HPV/p16 status	Is it HPV-positive or HPV-negative? (Determines staging system and prognosis)	p16 immunohistochemistry on biopsy specimen; ± HPV PCR/ISH
3. T staging (tumour extent)	How large is the primary? Does it invade adjacent structures?	Clinical examination + CT/MRI ^[2]^[4]
4. N staging (nodal status)	Are there lymph node metastases?	Clinical examination + ultrasound neck ± FNAC ^[2]^[4] + CT/MRI + PET-CT
5. M staging (distant metastasis)	Has it spread to distant sites?	CT thorax/abdomen, PET scan if necessary ^[4]
6. Synchronous primary screening	Is there a second primary tumour elsewhere in the aerodigestive tract?	Panendoscopy (10% risk of synchronous/metachronous tumour due to field cancerisation) ^[4]

Core Principle: Tissue Is the Issue

You cannot treat oropharyngeal carcinoma without histological confirmation. Every suspicious oropharyngeal lesion — mass, ulcer, asymmetric tonsil — must be biopsied. Clinical appearance alone can be misleading (lymphoma and minor salivary gland tumours can look similar). Furthermore, p16/HPV status is mandatory because it determines the staging system and treatment intensity.

3. Investigation Modalities — Detailed Breakdown

These are the first and most important "investigations." The lecture slides emphasise a structured approach:

History (from lecture slides ^[3]^[4]):

Sore throat — duration, unilateral vs bilateral, progressive?
Referred otalgia — ipsilateral ear pain with normal otoscopy is a red flag
Dysphagia, odynophagia — to solids, liquids, or both?
Muffled speech — "hot-potato" voice suggests tongue base involvement
Risk factors: smoking, alcohol, oral sex (HPV related) ^[3]
Constitutional symptoms — weight loss, appetite
Timeline — weeks to months of symptoms (acute onset → think infection, not cancer)

Physical Examination (from lecture slides ^[3]):

Mass / ulcer — inspect the oropharynx: open the mouth, depress the tongue, use a headlight
Trismus — ask the patient to open their mouth maximally; inter-incisal distance < 35 mm is trismus. Indicates pterygoid invasion = advanced disease
Asymmetrical tonsil — compare left and right; any unilateral enlargement or surface irregularity is suspicious
50% cervical LN ^[3] — systematic palpation of all cervical nodal levels (I–V, plus suboccipital and parotid regions); note size, consistency (firm/hard = suspicious), fixation, tenderness
Bimanual palpation of tongue base — the tongue base is difficult to see but can be palpated bimanually (one finger in the mouth, one finger externally submandibularly) to assess for deep tumour extent
Flexible nasendoscopy — performed in clinic; allows visualisation of the nasopharynx (rule out NPC), oropharynx, hypopharynx, and larynx (vocal cord mobility); essential for complete assessment
Cranial nerve examination — especially CN V3 (sensation), VII (facial symmetry), IX (gag reflex, palatal movement), X (vocal cord — hoarseness), XI (shoulder shrug), XII (tongue protrusion and deviation)

Why cranial nerves? Oropharyngeal tumours can invade the parapharyngeal space, which contains the carotid sheath and cranial nerves IX–XII. Advanced disease with skull base erosion can affect any of these.

Panendoscopy + biopsy ^[4] is the cornerstone investigation. Let's break down what this involves and why each component matters.

What is panendoscopy?

"Pan-" (Greek: all) + "endo-" (within) + "-scopy" (looking) = looking at everything inside. It is a comprehensive endoscopic examination of the entire upper aerodigestive tract performed under general anaesthesia.

Panendoscopy includes direct laryngoscopy, bronchoscopy and OGD ^[2]:

Component	What It Examines	Why It Is Done
Direct laryngoscopy	Oropharynx, hypopharynx, larynx (including vocal cord mobility)	Assess primary tumour extent; examine for hypopharyngeal or laryngeal extension; evaluate airway
Bronchoscopy	Tracheobronchial tree	Screen for synchronous lung/bronchial primary (especially in smokers)
OGD (oesophagogastroduodenoscopy)	Oesophagus, stomach	Patients who develop tumour in the oral cavity and the oropharynx are more likely to develop a second primary tumour in the upper oesophagus ^[2]

Biopsy during panendoscopy:

Incisional biopsy should be performed in all cases ^[2] — take representative tissue from the lesion edge (include both tumour and normal tissue at the margin)
If the primary is in the tonsil, tonsillectomy or EUA + Bx ^[4] can be performed — tonsillectomy provides the entire specimen for assessment and is particularly useful when:
- The tonsillar primary is occult (not visible on surface) but suspected based on p16-positive neck node
- Need to assess depth of invasion accurately
Assess tumour extent and look for synchronous tumour ^[2]

Why Panendoscopy Is Mandatory

10% risk of synchronous/metachronous tumour (field cancerisation) ^[4]. This means for every 10 patients with oropharyngeal SCC, 1 will have ANOTHER primary tumour somewhere else in the aerodigestive tract. If you skip panendoscopy, you may miss a second cancer in the oesophagus, larynx, or bronchus — and the patient's prognosis will be dramatically worse because you're treating only one of two cancers.

3.3 Pathological Tests on Biopsy/FNA Specimens

Once tissue is obtained, the following pathological assessments are performed:

3.4 Imaging Investigations

The purpose of imaging in oropharyngeal carcinoma is threefold:

Delineate the extent of the primary tumour (T staging)
Assess cervical lymph node status (N staging)
Screen for distant metastasis and synchronous primaries (M staging)

Ultrasound neck +/- FNAC ^[4]

Aspect	Details
Role	Primarily for assessment of cervical lymph nodes, NOT for the primary tumour (primary is deep in the oropharynx, beyond ultrasound's reach)
What it detects	Lymph node size, shape, echogenicity, presence of necrosis/cystic change, loss of fatty hilum
Key advantage	Real-time guidance for FNAC of suspicious nodes; no radiation; inexpensive
Limitations	USG has limited use in oropharyngeal cancer ^[2] — cannot assess the primary tumour depth, cannot evaluate retropharyngeal nodes or parapharyngeal space invasion
Suspicious LN features on USG	Rounded shape (loss of normal oval "kidney-bean" shape), loss of echogenic fatty hilum, heterogeneous echotexture, cystic change (particularly in HPV+ disease), peripheral vascularity on Doppler

CT ^[2]^[4] — the workhorse of head and neck cancer staging.

Aspect	Details
Protocol	Contrast-enhanced CT of the neck (axial + coronal + sagittal reformats); CT thorax ± abdomen for distant metastasis
Primary tumour	Useful to detect bony invasion ^[2] — CT is superior to MRI for demonstrating cortical bone destruction (e.g., mandibular invasion in T4a disease) ^[7]
Regional LN	Detection of cervical lymph node metastasis ^[2] — features of pathological nodes include: size > 1.0 cm in minimal axial diameter, rounded shape, heterogeneous enhancement, loss of normal fatty hilum, central necrosis ^[7]
Distant metastasis	CT thorax and abdomen to assess for distant metastasis ^[2] — screens for lung metastases (most common distant site), liver metastases, mediastinal lymphadenopathy
Advantages	Fast acquisition, wide availability, excellent spatial resolution, superior for bone assessment, can image the entire chest/abdomen in one session
Limitations	Radiation exposure; less detailed soft tissue contrast compared to MRI; dental amalgam artefact can degrade oral cavity/oropharyngeal images

Key CT findings in oropharyngeal carcinoma:

Primary: Enhancing mass in the tonsil/tongue base/soft palate with obliteration of normal tissue planes; invasion through pharyngeal constrictor into parapharyngeal fat (loss of the normal fat plane = invasion)
Mandible invasion: Cortical erosion or destruction of the ascending ramus (T4a)
Pathological nodes: Central necrosis (ring-enhancing node), cystic degeneration (HPV+ characteristic), extranodal extension (irregular nodal margin, infiltration into surrounding fat)

MRI ^[2]^[4] — the imaging modality of choice for cancer of the oral cavity and oropharynx ^[2].

Aspect	Details
Protocol	T1-weighted, T2-weighted, post-gadolinium T1 with fat suppression; DWI (diffusion-weighted imaging) increasingly used
Primary tumour	Provides optimal visualisation of soft-tissue infiltration of the tumour ^[2] — superior to CT for delineating tumour margins against surrounding muscle (e.g., extent of tongue base invasion, spread to intrinsic/extrinsic tongue muscles)
Bone marrow invasion	MRI is superior to CT for detecting bone marrow invasion of the mandible ^[7] — CT only sees cortical destruction, but MRI can detect marrow replacement before the cortex is breached
Perineural spread	MRI is the modality of choice for detecting perineural tumour spread (e.g., along CN V3 toward foramen ovale, or along CN XII in the hypoglossal canal) — seen as nerve thickening/enhancement
Skull base	MRI is superior for evaluating skull base erosion and intracranial extension
Regional LN	Detection of cervical lymph node metastasis ^[2] — similar criteria to CT but with better soft tissue contrast
Advantages	No radiation; superior soft tissue contrast; best for T staging in oropharynx; detects marrow invasion and perineural spread
Limitations	Longer acquisition time, motion artefact (swallowing), less available than CT, contraindicated with certain metallic implants, more expensive

Key MRI findings:

T1-weighted: Tumour appears isointense to slightly hypointense relative to muscle; replacement of normal high-signal parapharyngeal fat = evidence of lateral invasion
T2-weighted: Tumour appears hyperintense; useful for delineating tumour extent against surrounding muscle
Post-gadolinium T1 fat-sat: Tumour enhances; perineural spread seen as nerve enhancement and thickening
DWI: Tumour shows restricted diffusion (high cellularity) — useful for distinguishing tumour from post-treatment changes

CT vs MRI — When to Use Which?

Question	Best Modality	Why
Cortical bone invasion of mandible?	CT	CT has superior spatial resolution for cortical bone
Bone marrow invasion?	MRI	MRI detects marrow replacement before cortex is destroyed
Soft tissue extent of primary?	MRI	Superior soft tissue contrast — imaging modality of choice for oropharynx
Perineural spread?	MRI	Can see nerve enhancement/thickening on post-contrast sequences
Cervical lymph nodes?	Either; CT often first-line	Both detect size/necrosis; CT is faster and more widely available
Distant metastases?	CT thorax/abdomen	Fast, comprehensive, readily available
Skull base erosion?	MRI	Superior for detecting intracranial extension

In practice: Most patients get BOTH CT (for bone and distant metastasis) and MRI (for soft tissue T staging). They are complementary, not competing.

PET scan if necessary ^[4]

Aspect	Details
Tracer	18F-FDG (fluorodeoxyglucose) — a glucose analogue; cancer cells are metabolically hyperactive and take up more FDG → "hot spots"
Roles	(1) Detect occult primary when neck node is positive but no primary found on examination/CT/MRI; (2) Identify primary disease or detect distant metastatic disease ^[6]; (3) Detect synchronous primaries in the aerodigestive tract; (4) Post-treatment surveillance — distinguish recurrence from post-treatment fibrosis
Advantages	PET scan is superior to both CT and MRI for detecting regional nodal metastasis as well as distant metastasis and second primary tumours ^[7]; functional imaging (metabolic activity, not just anatomy)
Limitations	False positives from inflammation/infection; poor spatial resolution for small tumours ( < 8–10 mm); not useful immediately post-treatment (inflammation confounds); expensive; limited availability
When to use	Advanced disease (Stage III/IV) — screens for distant metastases that would change management from curative to palliative; occult primary workup; equivocal findings on CT/MRI

PET-CT vs Panendoscopy for synchronous tumour detection: Panendoscopy may identify synchronous primaries that are too small to be identified with PET scan ^[7], but PET scan may identify lower aerodigestive tract tumours not seen with panendoscopy ^[7]. They are complementary — both should be done in appropriate patients.

While there is no diagnostic blood test for oropharyngeal carcinoma, baseline bloods are important for:

Test	Purpose
FBC	Baseline for treatment planning (anaemia from chronic disease/bleeding; leucocyte count for fitness for chemotherapy)
Renal function (Cr, eGFR)	Required before contrast CT; cisplatin is nephrotoxic — need baseline before chemotherapy
Liver function (LFT)	Baseline for chemotherapy; screen for liver metastasis (elevated ALP, GGT)
Thyroid function (TFT)	Baseline before radiotherapy — radiation to the neck can cause hypothyroidism
Nutritional markers (albumin, pre-albumin)	Many patients are malnourished from dysphagia; low albumin predicts poor surgical outcomes
EBV DNA (plasma)	To exclude NPC as the primary (relevant in Hong Kong)
Coagulation (PT/APTT)	Pre-operative assessment

When all investigations are complete, you should be able to answer:

Question	Investigation That Answers It
What is the histological diagnosis?	Biopsy (H&E staining)
Is it HPV-positive or HPV-negative?	p16 IHC ± HPV DNA/RNA ISH
What is the T stage?	Clinical examination + MRI (primary modality) + CT (bony invasion)
What is the N stage?	Clinical examination + USG ± FNAC + CT/MRI + PET-CT
What is the M stage?	CT thorax/abdomen + PET-CT
Is there a synchronous primary?	Panendoscopy + PET-CT
Is the patient fit for treatment?	Blood tests, nutritional assessment, dental evaluation, airway assessment

The completed staging is then presented at the Head and Neck Multidisciplinary Team (MDT) meeting where surgeons, oncologists, radiologists, pathologists, and allied health professionals collectively decide the optimal treatment plan.

High Yield Summary

Diagnosis of oropharyngeal carcinoma requires histological confirmation — always biopsy.

Workup per lecture slides ^[4]:

History and Physical Examination (including flexible nasendoscopy)
Panendoscopy + biopsy — confirms histology; 10% risk of synchronous/metachronous tumour
Tonsillectomy or EUA + Bx — especially for occult tonsillar primary
Ultrasound neck +/- FNAC — FNA for cytology + p16/HPV testing on neck nodes
CXR — initial screen
CT / MRI — CT for bone and distant metastasis; MRI is the imaging modality of choice for oropharynx (soft tissue)
PET scan if necessary — for advanced disease, occult primary, distant metastasis

p16 IHC is the standard surrogate marker for HPV status. Positive = ≥ 70% diffuse nuclear + cytoplasmic staining → use AJCC 8th Ed HPV-positive staging.

CT vs MRI: CT better for cortical bone invasion; MRI better for soft tissue extent, marrow invasion, perineural spread. In practice, get BOTH.

FNA of nodes: Useful for cytology + HPV PCR; does NOT provide tissue architecture (cannot subtype lymphoma).

Panendoscopy = direct laryngoscopy + bronchoscopy + OGD: Mandatory for synchronous primary screening.

Active Recall - Diagnosis and Investigations of Oropharyngeal Carcinoma

References

^[2] Senior notes: felixlai.md (CA Oropharynx — Diagnosis section, field cancerisation, patterns of metastasis) ^[3] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p37 — History and Examination) ^[4] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p42 — Workup and Investigation) ^[6] Senior notes: felixlai.md (Pathological tests — FNA, biopsy, HPV/EBV PCR) ^[7] Senior notes: felixlai.md (H&N cancer — Radiological tests: CT, MRI, panendoscopy, PET scan)

Management of Oropharyngeal Carcinoma

Before diving into the algorithm, let's establish the overarching philosophy. The lecture slides lay out a clear management framework that applies across all head and neck cancers, with specific nuances for the oropharynx:

Management Framework — General Principle ^[8]:

Tumour clearance with long-term survival benefit
Organ and function preservation
When surgery is indicated → Resection with adequate margins → Reconstruction for Form and Function → Rehabilitation always — swallowing, voice and hearing

This triad — Resection, Reconstruction, Rehabilitation — is the backbone of all H&N surgical oncology. You never just cut; you must plan how to rebuild and how to restore function.

Management is based on TNM staging ^[8]:

Stage	Treatment Philosophy
Early stage (I, II)	Single modality of treatment — Surgery or radiotherapy alone ^[8]
Late stage (III, IV)	Combined modality of treatment — Concurrent chemo-irradiation OR Surgery with adjuvant radiotherapy ± chemotherapy ^[8]

General rule ^[8]:

Early stage: radiotherapy or minimally invasive surgery (laser/robotic)
Late stage: Surgery with adjuvant treatment

BUT — there are important site-specific exceptions ^[8]:

Oral cavity and thyroid: surgery in early stage (oral cavity tumours respond less well to radiotherapy; thyroid is surgically accessible)
NPC: chemo-irradiation in late stage (NPC is exquisitely radiosensitive + surgically inaccessible at the skull base)

For the oropharynx specifically, the approach has unique features ^[2]:

Tumours of the oropharynx tend to be chemosensitive ^[2] — this is why chemoradiation plays such a central role, often as an alternative to surgery
Adequate treatment of the neck is important because of high risk of regional metastasis ^[2] — with 50% of patients presenting with nodal disease, the neck must be addressed in every treatment plan
Multidisciplinary approach including swallowing rehabilitation is important ^[2]

Oropharynx Is Different from Oral Cavity

For oral cavity cancers, surgery is preferred even in early stages because the oral cavity is accessible and radiation has significant morbidity (xerostomia, ORN). For oropharyngeal cancers, particularly HPV-positive tumours, chemoradiation is often preferred because: (1) the oropharynx is less surgically accessible, (2) oropharyngeal SCC is highly chemo- and radiosensitive, and (3) organ preservation (swallowing, speech) is paramount. Don't confuse the two — the management frameworks are different.

3. Treatment Modalities — Detailed Breakdown

3.1 Surgery

Minimally invasive technique to resect tumours of oropharynx include a transoral robotic surgical approach (TORS) ^[2].

Aspect	Details
What it is	Robotic-assisted transoral surgery using the da Vinci surgical system; binocular 3D vision + articulating instruments pass through the mouth to resect the tumour
Why it was developed	Previously, procedures might otherwise require a lip-splitting mandibulotomy approach to resect tumours of the oropharynx ^[2] — mandibulotomy is a major open procedure where the mandible is divided to gain access to the oropharynx, carrying significant morbidity (malocclusion, plate complications, prolonged recovery)
Advantages	Associated with shorter length of hospital stay and less likely to be gastrostomy tube or tracheostomy dependent at 6 months ^[2]; excellent visualisation of tongue base and tonsil; avoids mandibulotomy; less tissue destruction → better functional outcomes
Indications	Early-stage (T1–T2) oropharyngeal SCC, selected T3 tumours; particularly useful for tonsillar and tongue base tumours
Contraindications	Trismus (cannot open mouth for transoral access); tumours encasing the carotid artery; extensive mandibular invasion; tumours too lateral/posterior for transoral reach
What is resected	Primary tumour with adequate margins (radical tonsillectomy for tonsillar SCC, tongue base resection for tongue base tumours)

Minimal invasion surgery: Laser/endoscopic/robotic partial pharyngectomy ± reconstruction ^[9]

For larger or more advanced tumours where transoral access is insufficient:

Open major surgery with reconstruction ^[9]:

Procedure	Indication
Mandibulotomy approach	Access to tongue base/parapharyngeal space tumours too large for TORS; mandible is temporarily divided (lip-splitting approach) and re-plated
Partial pharyngectomy	Resection of the involved portion of the oropharyngeal wall
Circumferential pharyngectomy + reconstruction ^[9]	When the tumour involves the circumference of the pharynx — requires free flap reconstruction (e.g., jejunal free flap, anterolateral thigh flap) to restore the pharyngeal conduit
Pharyngo-laryngo-oesophagectomy (PLO) ^[9]	Extensive tumour involving pharynx, larynx and cervical oesophagus — a massive operation with significant morbidity; requires gastric pull-up or jejunal free flap for reconstruction

Adequate treatment of the neck is important because of high risk of regional metastasis ^[2].

Type	What Is Removed	Indication
Selective neck dissection	Selected lymph node levels (typically II–IV) while preserving IJV, CN XI, SCM	Clinically N0 neck with > 15–20% risk of occult metastasis (applies to most oropharyngeal SCC); ipsilateral for unilateral tumours, bilateral for midline tumours (tongue base, soft palate)
Modified radical neck dissection	Levels I–V LN; preserves one or more of: IJV, CN XI, SCM	Clinically positive neck (N+) disease
Radical neck dissection	Levels I–V LN + IJV + CN XI + SCM — all removed	Extensive nodal disease with gross involvement of IJV/SCM/CN XI; now rarely performed as modified radical achieves comparable oncological outcomes

Why bilateral neck dissection for midline tumours? The tongue base and soft palate straddle the midline. Lymphatic drainage from midline structures goes bilaterally — to both right and left Level II–IV nodes. Treating only one side leaves the contralateral neck at risk.

Elective Neck Dissection

15–20% of occult nodal metastasis ^[10] — even when the neck is clinically and radiologically N0, there is a significant risk of microscopic disease in the lymph nodes. This is why elective (prophylactic) neck dissection is performed — to remove microscopic disease before it becomes macroscopic. The threshold for elective neck dissection is generally accepted as > 15–20% risk of occult nodal metastasis.

Reconstruction for Form and Function ^[8]:

After surgical resection, the defect must be reconstructed to restore:

Swallowing — maintain oropharyngeal conduit patency and tongue base contact with palate
Speech — preserve velopharyngeal closure (soft palate function) and tongue mobility
Airway — prevent aspiration

Reconstruction Method	When Used
Primary closure	Small defects that can be closed directly
Local/regional flaps (e.g., buccal fat pad flap, submental flap)	Moderate defects
Free tissue transfer — fasciocutaneous flaps (e.g., radial forearm free flap, anterolateral thigh flap)	Larger defects; provides soft tissue bulk for tongue base/pharyngeal wall reconstruction
Osseous free flaps (e.g., fibula free flap)	When mandibular reconstruction is needed following segmental mandibulectomy

3.2 Radiotherapy (RT)

Radiotherapy is a cornerstone of oropharyngeal carcinoma treatment — both as primary definitive therapy and as adjuvant post-operative treatment.

Aspect	Details
Indication	Early-stage (I–II) oropharyngeal SCC as single modality; locoregionally advanced disease as concurrent chemoradiation; patients medically unfit for surgery
Technique	Intensity-modulated radiotherapy (IMRT) is the current standard — allows dose sculpting to conform radiation to the tumour while sparing adjacent normal structures (especially parotid glands → reduces xerostomia)
Dose	Typically 70 Gy in 35 fractions (2 Gy/fraction, 7 weeks) for definitive treatment
Radiation fields	Primary tumour + bilateral neck (because of high risk of bilateral nodal disease from oropharynx)

Early stage: radiotherapy or minimally invasive surgery (laser/robotic) ^[8] — for early oropharyngeal SCC, definitive RT and TORS are both acceptable options. The choice depends on institutional expertise, patient preference, and anticipated functional outcomes.

Post-operative RT ± chemotherapy: indicated for patients who have close or positive margins or factors increasing risk of local recurrence including lymphovascular invasion, perineural invasion and extranodal extensions (ENE) ^[7]

Indication for PORT	Rationale
Positive or close margins	Residual microscopic tumour at the surgical margin → RT sterilises remaining cells
Perineural invasion (PNI)	Tumour cells tracking along nerves can extend far beyond the visible tumour margin → RT covers the nerve pathway
Lymphovascular invasion (LVI)	Indicates systemic/regional spread potential beyond what surgery removed
Extranodal extension (ENE)	Tumour has breached the lymph node capsule → dramatically increases risk of locoregional recurrence
Multiple positive nodes	Higher tumour burden in the neck
pT3–T4 tumour	Advanced primary warrants adjuvant treatment

When to add chemotherapy to PORT: If the patient has positive margins or extranodal extension (ENE), concurrent chemotherapy (cisplatin) is added to PORT — these two features are the strongest indications for chemo-RT over RT alone post-operatively, based on the landmark EORTC 22931 and RTOG 9501 trials.

3.3 Chemotherapy

Chemotherapy in oropharyngeal carcinoma is almost always used in combination with radiotherapy (concurrent chemoradiation, CRT) — it is rarely used as a standalone curative treatment.

Concomitant chemoradiation is commonly utilised in advanced stage (III and IV) oropharyngeal carcinoma which effectively preserves function and is associated with survival comparable to surgery with postoperative radiation ^[2].

Aspect	Details
Standard regimen	Cisplatin 100 mg/m² IV on days 1, 22, and 43 of radiotherapy (3 cycles concurrent with RT)
Mechanism	Cisplatin is a radiosensitiser — it forms DNA cross-links that impair DNA repair, making cancer cells more susceptible to radiation-induced damage. The combination is synergistic, not just additive.
Why not chemotherapy alone?	Chemotherapy alone cannot cure oropharyngeal SCC. It reduces tumour bulk but does not eradicate locoregional disease. RT provides the definitive locoregional control.
Alternative for cisplatin-unfit patients	Carboplatin (less nephrotoxic but less efficacious); cetuximab (anti-EGFR monoclonal antibody) + RT — though recent evidence (De-ESCALaTE, RTOG 1016) shows cetuximab + RT is inferior to cisplatin + RT for HPV-positive disease

For patients with distant metastatic disease (Stage IVC) or recurrent disease not amenable to salvage surgery or re-irradiation:

Agent	Mechanism	Indication
Cisplatin or carboplatin + 5-FU	Platinum-based cytotoxic chemotherapy	First-line palliative chemotherapy
Pembrolizumab (anti-PD-1)	Immune checkpoint inhibitor — blocks PD-1 on T cells → restores anti-tumour immune response	First-line for recurrent/metastatic HNSCC (alone if PD-L1 CPS ≥ 1, or combined with platinum/5-FU — KEYNOTE-048 trial)
Nivolumab (anti-PD-1)	Same mechanism as pembrolizumab	Second-line for platinum-refractory recurrent/metastatic HNSCC (CheckMate 141)
Cetuximab (anti-EGFR)	Monoclonal antibody targeting EGFR → inhibits proliferation, induces apoptosis, enhances radiosensitivity	Combined with platinum-based chemo in first-line (EXTREME regimen); or with RT when cisplatin contraindicated

Immunotherapy in oropharyngeal SCC: HPV-positive tumours have a higher tumour mutational burden and more immune infiltration — they tend to respond well to checkpoint inhibitors. Pembrolizumab has become a game-changer for recurrent/metastatic disease.

This is one of the hottest topics in head and neck oncology right now. The rationale:

De-intensification of treatment can be considered while obtaining the same locoregional and overall survival seen with standard treatment options ^[2].

Why de-intensify?

HPV-positive patients are younger (40–60), have excellent prognosis (~80% 5-year survival), and will live long enough to suffer from late treatment toxicities
Standard CRT causes: severe xerostomia, dysphagia, fibrosis, dental decay, hypothyroidism, hearing loss, osteoradionecrosis — these are lifelong problems
If we can achieve the same cure rate with less intensive treatment, we spare patients decades of morbidity

Current de-intensification strategies (under investigation in clinical trials):

Strategy	Approach	Status
Reduced RT dose after good response to induction chemo	If induction TPF → excellent response → reduce RT from 70 Gy to 54 Gy	Clinical trials (e.g., ECOG-ACRIN E1308)
TORS + reduced-dose adjuvant RT	Surgery first → if pathology favourable → reduce or omit adjuvant RT	Clinical trials (e.g., ECOG E3311)
Replace cisplatin with cetuximab	Less toxic than cisplatin	Abandoned — RTOG 1016 and De-ESCALaTE showed inferior outcomes with cetuximab + RT vs cisplatin + RT
Omit chemotherapy	RT alone for favourable-risk HPV+ patients	Under investigation

Critical Update: Cetuximab + RT Is NOT Equivalent to Cisplatin + RT

The RTOG 1016 and De-ESCALaTE trials definitively showed that for HPV-positive oropharyngeal SCC, cetuximab + RT is inferior to cisplatin + RT in terms of overall survival and locoregional control. Do NOT use cetuximab as a de-intensification substitute for cisplatin in HPV-positive disease. Cisplatin remains the standard. De-intensification must be pursued through other strategies (reduced dose, reduced volume) within clinical trials.

3.5 Specific Management by Stage

Early stage (I, II): Single modality of treatment — Surgery or radiotherapy alone ^[8]

Option	Details	When to Choose
Definitive RT (IMRT)	70 Gy/35# to primary + bilateral neck	Excellent option for most early oropharyngeal SCC; preserves anatomy; avoids surgical morbidity
TORS ± selective neck dissection	Transoral resection of primary + ipsilateral or bilateral selective neck dissection (levels II–IV)	Preferred when: clear surgical margins achievable, desire to avoid RT (preserve RT as salvage option), small tonsillar or tongue base tumour amenable to transoral approach

Post-operative adjuvant treatment after surgery:

No adverse features → observation and surveillance
Adverse features (positive margins, LVI, PNI, ENE, tumour thickness > 4 mm) → post-operative radiotherapy ± concurrent chemotherapy ^[2]^[7]

Rehabilitation always — swallowing, voice and hearing ^[8]

This is not an afterthought — it is integral to the treatment plan:

Domain	Intervention	Why
Swallowing	Pre-treatment speech pathologist assessment; swallowing exercises during and after RT; modified diet consistency; PEG/RIG tube for enteral feeding if needed	RT causes mucositis → fibrosis → pharyngeal stricture → long-term dysphagia. Proactive swallowing rehabilitation reduces severity.
Speech	Speech therapy; prosthetic rehabilitation if soft palate resected	Oropharyngeal surgery/RT affects velopharyngeal closure and tongue base mobility
Nutrition	Dietitian involvement; prophylactic PEG in patients expected to have > 10% weight loss during CRT	Mucositis from CRT causes severe odynophagia; patients cannot eat → malnutrition → treatment breaks → worse outcomes
Dental	Pre-RT dental assessment; extraction of compromised teeth; lifelong fluoride trays	Prevents osteoradionecrosis (ORN) of the mandible
Airway	ALWAYS protect the airway for all H&N cancer ^[2]; tracheostomy if airway threatened	Bulky tumours or post-treatment oedema can obstruct the airway
Psychosocial	Psychology/psychiatry input; support groups	H&N cancer profoundly affects appearance, eating, speaking → depression, social isolation
Smoking cessation	Mandatory; continued smoking during RT reduces cure rate by 50% and increases toxicity	Smoking causes vasoconstriction → reduces tumour oxygenation → radiation is less effective in hypoxic tissue
Hearing	Audiometry before and after cisplatin	Cisplatin is ototoxic (damages cochlear hair cells)

Post-treatment surveillance is critical because:

Early detection of recurrence allows salvage treatment
Detection of metachronous second primaries (field cancerisation)
Management of late treatment toxicities

Timeframe	Schedule	Assessments
Year 1–2	Every 1–3 months	Clinical exam, flexible nasendoscopy, thyroid function (if neck irradiated)
Year 3–5	Every 3–6 months	As above
Year 5+	Annually	As above; lifelong due to second primary risk
Post-CRT response assessment	PET-CT at 12 weeks post-CRT	If complete metabolic response → surveillance. If residual FDG uptake in neck → consider salvage neck dissection

EARLY REFERRAL to ENT Surgeons when suspecting malignancy ^[11]:

Persistent 2–4 weeks after conservative/empirical treatment
Clinically suspicious: irregular, induration, > 2 cm, associated cervical LN enlargement

High Yield Summary

Management framework per lecture slides ^[8]:

Early stage (I, II) → single modality: surgery OR radiotherapy alone
Late stage (III, IV) → combined modality: concurrent CRT OR surgery + adjuvant RT ± chemo
General rule: Early = RT or minimally invasive surgery; Late = surgery + adjuvant
BUT: Oral cavity = surgery early; NPC = chemo-irradiation late
General principle: Tumour clearance + Organ/function preservation + Reconstruction for form and function + Rehabilitation always

Oropharynx-specific points ^[2]:

Oropharyngeal tumours are chemosensitive → CRT is a mainstay
TORS replaces the old lip-splitting mandibulotomy → shorter hospital stay, less morbidity
Adequate neck treatment is essential — 50% have nodal disease at presentation
CRT effectively preserves function with survival comparable to surgery + PORT

HPV-positive disease ^[2]:

Better prognosis, higher chemo-response, de-intensification being studied
Cetuximab + RT is NOT a valid de-intensification strategy (inferior to cisplatin + RT)
Cisplatin + RT remains the standard concurrent regimen

Adjuvant treatment after surgery ^[7]:

PORT indicated for: positive margins, PNI, LVI, ENE, advanced T stage
Add cisplatin to PORT if: positive margins or ENE

Metastatic/recurrent disease: Pembrolizumab ± platinum/5-FU (immunotherapy era)

Supportive care: Dental assessment pre-RT, nutritional support, swallowing rehabilitation, smoking cessation, airway protection — all mandatory.

Refer early: Persistent > 2–4 weeks, irregular, indurated, > 2 cm, cervical LN ^[11].

Active Recall - Management of Oropharyngeal Carcinoma

References

^[2] Senior notes: felixlai.md (CA Oropharynx — Treatment section, general principles, TORS, chemoradiation) ^[7] Senior notes: felixlai.md (H&N cancer — Treatment of localised and locoregionally advanced cancers, post-operative RT indications) ^[8] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p43, p44 — Management Framework) ^[9] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p47 — Minimal invasion surgery, open surgery, PLO) ^[10] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p35 — 15-20% occult nodal metastasis, elective neck dissection) ^[11] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p48 — Take Home Message, early referral criteria)

Complications of Oropharyngeal Carcinoma

Complications in oropharyngeal carcinoma fall into three major categories: (1) complications of the disease itself (what the tumour does if untreated or progresses), (2) complications of treatment (surgery, radiotherapy, chemotherapy), and (3) long-term sequelae affecting quality of life. Understanding these from first principles — what the tumour invades, what the treatment destroys — makes them easy to reason through rather than memorise.

Head and neck cancer poses special challenges in both resection and reconstruction ^[12]. The oropharynx is at the crossroads of breathing, swallowing, and speaking — any disease or treatment that disrupts this region has profound functional consequences.

Anatomical disruption will affect morphology and physiology ^[12] — this is the core principle. Every complication below can be traced back to which anatomical structure has been damaged (by tumour or by treatment) and what function that structure normally serves.

1. Complications of the Disease Itself (Untreated or Progressive Tumour)

2. Complications of Treatment

2.1 Complications of Surgery

Complication	Mechanism	Management
Haemorrhage	Injury to lingual artery, facial artery, or branches of external carotid during resection; risk increases with re-operation in irradiated fields	Meticulous haemostasis; ligation or cauterisation; interventional radiology for major vessel injury
Airway obstruction	Post-operative oedema of tongue base/pharynx; haematoma compressing the airway	Prophylactic tracheostomy in major resections; close monitoring; return to theatre for haematoma evacuation

Complication	Mechanism	Management
Wound infection / breakdown	Contamination from oral flora (the oropharynx is a "clean-contaminated" field); impaired healing in malnourished or previously irradiated tissue	Antibiotics; wound care; may require return to theatre for debridement
Orocutaneous / pharyngocutaneous fistula	Breakdown of the pharyngeal repair → saliva leaks through the surgical wound to the skin surface	NPO (nil per os), nutritional support via NG/PEG, wound care; may heal conservatively or require surgical repair
Flap failure (in reconstructive cases)	Venous thrombosis or arterial insufficiency of the free flap → flap necrosis	Close flap monitoring (colour, capillary refill, Doppler); return to theatre for re-exploration within 6 hours if compromised
Aspiration	Loss of tongue base bulk after glossectomy or loss of pharyngeal sensation → impaired swallowing mechanics → aspiration	Swallowing rehabilitation ^[8]; modified diet; Mendelsohn manoeuvre; in severe cases, temporary tracheostomy with cuffed tube

Complication	Mechanism	Management
Dysphagia	Voluntary phase usually affected by tumours in the head and neck region; usually immediately after glossectomy or pharyngectomy ^[12]; loss of tongue base contact with palate → impaired bolus propulsion	Rehabilitation always — swallowing, voice and hearing ^[8]; speech pathologist; diet modification; prosthetic augmentation to allow tongue-palate contact
Speech impairment	Resection of soft palate → velopharyngeal insufficiency (nasal regurgitation, hypernasal speech); resection of tongue base → impaired articulation	Speech therapy; palatal prosthesis (obturator) for soft palate defects; prosthetic augmentation
Trismus (post-surgical)	Fibrosis and scarring in the pterygoid region or temporomandibular joint area after surgery	Physiotherapy; jaw-stretching exercises (Therabite device); prevention better than cure
Neck and shoulder dysfunction	CN XI (spinal accessory nerve) injury during neck dissection → trapezius denervation → shoulder drop, difficulty abducting arm above horizontal	Physiotherapy; modified radical neck dissection preserves CN XI when oncologically safe
Lymphoedema (facial/submental)	Disruption of lymphatic channels during neck dissection; particularly bilateral neck dissection	Lymphatic massage; compression garments

Why Does Glossectomy Cause Dysphagia?

The voluntary phase of swallowing is usually affected by tumours in the head and neck region ^[12]. The tongue base is the engine of the oropharyngeal swallow — it pushes the bolus posteriorly against the posterior pharyngeal wall and into the pharynx. After partial or total glossectomy, the tongue base remnant cannot generate sufficient force to propel the bolus → food pools in the valleculae and pyriform sinuses → aspiration risk. Reconstruction using soft tissue free flaps (e.g., radial forearm, ALT flap) provides bulk to restore tongue-palate contact, but motor function cannot be replaced.

2.2 Complications of Radiotherapy

Radiotherapy to the oropharynx and bilateral neck is associated with a wide spectrum of acute and late toxicities. The principle is straightforward: radiation damages all rapidly dividing cells (both tumour and normal tissue) within the radiation field.

Complication	Mechanism	Clinical Features and Management
Mucositis	Radiation destroys the rapidly dividing basal cells of the oropharyngeal mucosa → mucosal breakdown, ulceration, pseudomembrane formation	Severe pain → odynophagia → inability to eat → weight loss. Dose-limiting toxicity. Management: analgesics (topical and systemic), magic mouthwash (lidocaine + antacid + diphenhydramine), nutritional support (NG/PEG), meticulous oral hygiene
Radiation dermatitis ^[13]	Radiation damages skin epithelium → erythema → dry desquamation → moist desquamation	Skincare: gentle washing, moisturisers, avoid trauma to irradiated skin; severe cases need wound care
Dysphagia and odynophagia ^[13]	Mucositis of the pharynx + oedema of pharyngeal muscles → pain and mechanical obstruction during swallowing	As above for mucositis; proactive swallowing exercises to prevent fibrosis
Taste alteration (dysgeusia)	Radiation damages taste buds on the tongue → loss of taste	Usually partially recovers over 6–12 months post-RT; zinc supplementation may help
Salivary gland dysfunction (early xerostomia)	Radiation damages serous acinar cells of the parotid and submandibular glands (serous cells are more radiosensitive than mucinous cells) → reduced salivary flow, thick/ropey saliva	Pilocarpine (muscarinic agonist — stimulates residual salivary tissue); artificial saliva; IMRT spares contralateral parotid to preserve some function

Complication	Mechanism	Clinical Features and Management
Xerostomia (chronic)	Permanent destruction of salivary acinar cells → irreversible reduction in salivary flow (if > 25–30 Gy to parotid glands)	Lifelong dry mouth → dental caries (saliva normally buffers acid and remineralises enamel), difficulty eating dry food, altered taste, increased oral infections (candidiasis). Management: pilocarpine, artificial saliva, rigorous dental care, fluoride trays
Osteoradionecrosis (ORN) of the mandible	Radiation → endarteritis obliterans of mandibular blood supply (reduced vascularity) + hypocellularity + hypoxia of bone → impaired healing capacity. Any trauma (tooth extraction, denture pressure) in irradiated bone → non-healing wound → progressive bone necrosis	Exposed, non-healing mandibular bone; pain; pathological fracture; fistula. Prevention: pre-RT dental assessment and extraction of compromised teeth. Treatment: hyperbaric oxygen (controversial), pentoxifylline + vitamin E (PENTOCLO protocol), sequestrectomy, free flap reconstruction for severe cases
Pharyngeal stenosis (stricture) ^[13]	Radiation-induced fibrosis of pharyngeal muscles and submucosa → progressive narrowing of the pharyngeal lumen	Progressive dysphagia months-years after RT; diagnosed on barium swallow or endoscopy. Treatment: endoscopic dilatation; prevention through proactive swallowing exercises during and after RT
Hypothyroidism	Radiation to bilateral neck → direct thyroid gland damage + vascular compromise → thyroid failure	Occurs in 20–50% of patients receiving neck irradiation. Screen with TSH every 6–12 months post-RT. Treatment: levothyroxine replacement
Hearing loss (sensorineural)	If radiation field includes the cochlea (e.g., for tumours extending to parapharyngeal space/skull base) → damage to cochlear hair cells	Audiometry monitoring; hearing aids if needed
Laryngeal oedema ^[13]	Radiation-induced lymphatic obstruction and inflammation in the larynx → chronic swelling	Hoarseness, stridor in severe cases; steroids for acute flares; tracheostomy if airway compromise
Carotid artery stenosis	Radiation → accelerated atherosclerosis and intimal fibrosis of the carotid arteries (within the radiation field) → progressive stenosis	Increased long-term risk of stroke/TIA. Screening with carotid Doppler USG recommended 5+ years post-RT
Radiation-induced second malignancy	Radiation is itself a carcinogen → can induce new primary tumours in the irradiated field after a latency of 5–20+ years	Sarcoma (most common radiation-induced malignancy), second SCC. Rare but important for long-term survivors — especially young HPV-positive patients
Soft tissue fibrosis / trismus	Fibrosis of masticatory muscles (masseter, pterygoids) → progressive restriction of mouth opening	Jaw-stretching physiotherapy (Therabite); prevention with exercises during RT
Sometimes delayed presentation of swallowing dysfunction after radiotherapy ^[12]	Progressive fibrosis of pharyngeal constrictors → "late radiation-associated dysphagia" (late-RAD); can present months to years after RT completion even in patients who initially recovered	Proactive swallowing therapy; dilatation; PEG if severe

Why Does RT Cause ORN Specifically in the Mandible?

The mandible is uniquely vulnerable because: (1) it receives most of its blood supply from the inferior alveolar artery — a single end-artery — so radiation-induced endarteritis causes critical ischaemia with no collateral rescue, (2) the mandible is dense cortical bone with low cellularity and slow turnover, so healing capacity is already limited, and (3) the mandible is directly adjacent to the oropharyngeal mucosal tumour, so it is unavoidably within the high-dose radiation field. The maxilla, by contrast, has a rich dual blood supply and is rarely affected by ORN.

Chemotherapy (primarily cisplatin) carries systemic toxicities:

Complication	Mechanism	Management
Nephrotoxicity	Cisplatin → direct tubular damage → acute kidney injury; dose-limiting toxicity	Aggressive IV hydration pre/post cisplatin; monitor creatinine and eGFR; switch to carboplatin if renal impairment
Ototoxicity	Cisplatin → damage to outer hair cells of the cochlea → high-frequency sensorineural hearing loss (irreversible)	Pre-treatment and serial audiometry; dose adjustment if significant hearing loss
Nausea and vomiting	Cisplatin is highly emetogenic → stimulates CTZ (chemoreceptor trigger zone) and peripheral 5-HT3 receptors in the gut	Prophylactic anti-emetics: 5-HT3 antagonist (ondansetron) + NK1 antagonist (aprepitant) + dexamethasone
Myelosuppression	All cytotoxic agents → bone marrow suppression → neutropenia, anaemia, thrombocytopenia	Monitor FBC; neutropenic sepsis protocol if febrile + neutropenic (urgent IV broad-spectrum antibiotics); G-CSF if recurrent
Mucositis (additive with RT)	Chemotherapy + RT = synergistic mucosal toxicity	As per RT mucositis management above; often dose-limiting in concurrent CRT
Peripheral neuropathy	Cisplatin → damage to dorsal root ganglia → sensory neuropathy (numbness, tingling in hands/feet)	Dose-dependent; partially reversible; no specific treatment

Immune checkpoint inhibitors (pembrolizumab, nivolumab) are used in recurrent/metastatic disease and have a unique side-effect profile:

Complication	Mechanism	Key Examples
Immune-related adverse events (irAEs)	Checkpoint inhibitors remove the "brakes" on the immune system → T cells attack normal tissues (autoimmune phenomenon)	Pneumonitis, colitis, hepatitis, thyroiditis (hypo/hyperthyroidism), dermatitis, myocarditis, adrenalitis, hypophysitis
Management principle	Hold immunotherapy; corticosteroids for moderate-severe irAEs; specialist input for organ-specific toxicity	Grade 1–2: monitor ± steroids; Grade 3–4: high-dose steroids, discontinue drug, consider additional immunosuppression (infliximab for colitis, mycophenolate for hepatitis)

These are often underappreciated but profoundly impact patients:

Domain	Mechanism	Approach
Depression and anxiety	Disfigurement, dysphagia, dysphonia, social isolation, fear of recurrence	Psychological/psychiatric support; antidepressants; support groups
Social isolation	Inability to eat normally (tube feeding), speech changes, facial disfigurement → patients avoid social situations	MDT approach; speech therapy; social worker involvement
Body image disturbance	Most frequently exposed region of the body ^[12] — head and neck are visible; surgical scars, tracheostomy, PEG visible to others	Counselling; reconstructive surgery to optimise cosmesis; prosthetic rehabilitation
Financial hardship	Prolonged treatment course (7 weeks CRT), inability to work during treatment, ongoing rehabilitation	Social worker support; disability assessment

Head and neck cancer poses special challenges in both resection and reconstruction ^[12] — individualise the option of surgery to achieve the best functional and cosmetic result ^[12].

Timing	Disease Complications	Treatment Complications
At presentation	Airway compromise, aspiration, malnutrition, cranial nerve palsies, nodal/distant metastasis	—
During treatment	—	Mucositis, radiation dermatitis, dysphagia, nausea/vomiting, myelosuppression, nephrotoxicity
Early post-treatment	—	Wound infection/breakdown, fistula, flap failure, aspiration, haematoma
Late post-treatment	Recurrence, metachronous second primary	Xerostomia, ORN, pharyngeal stenosis, hypothyroidism, carotid stenosis, trismus, late-RAD dysphagia, radiation-induced second malignancy, hearing loss
Lifelong	Second primary (field cancerisation)	Xerostomia, dental caries, psychosocial impact, body image, depression

High Yield Summary

Disease complications: Airway compromise (always protect airway), haemorrhage (carotid blowout in advanced/recurrent disease), aspiration pneumonia, malnutrition/cachexia, cranial nerve palsies (parapharyngeal invasion → CN IX–XII), distant metastasis (lung, liver, bone, brain), synchronous/metachronous second primaries (10% risk, field cancerisation).

Surgical complications: Haemorrhage, airway obstruction, wound infection, orocutaneous/pharyngocutaneous fistula, flap failure, dysphagia (loss of tongue base bulk), speech impairment, CN XI injury (shoulder drop), trismus (post-operative fibrosis).

Radiotherapy complications:

Acute: mucositis (dose-limiting), radiation dermatitis, dysphagia/odynophagia, dysgeusia, early xerostomia
Late: chronic xerostomia, osteoradionecrosis (ORN) of mandible (prevention: pre-RT dental assessment), pharyngeal stenosis, hypothyroidism (screen TSH), carotid stenosis (stroke risk), late-RAD dysphagia, radiation-induced second malignancy

Chemotherapy complications: Cisplatin → nephrotoxicity, ototoxicity, nausea/vomiting, myelosuppression, peripheral neuropathy, additive mucositis with RT.

Immunotherapy complications: irAEs — pneumonitis, colitis, hepatitis, thyroiditis; manage with steroids.

Psychosocial: Depression, social isolation, body image disturbance — head and neck is the most frequently exposed region of the body. Individualise surgery for best functional and cosmetic result.

Rehabilitation always — swallowing, voice and hearing ^[8].

Active Recall - Complications of Oropharyngeal Carcinoma

References

^[2] Senior notes: felixlai.md (CA Oropharynx — overview, patterns of metastasis, field cancerisation, airway protection) ^[4] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p42 — 10% synchronous/metachronous tumour risk) ^[8] Lecture slides: GC 219. Infections and tumours in pharynx and oral cavity.pdf (p44 — Management Framework: rehabilitation always — swallowing, voice and hearing) ^[12] Lecture slides: GC 187. Head and neck cancer problems Function and shape.pdf (p4 — anatomical disruption, most exposed region; p9 — swallowing voluntary phase; p27 — special challenges, individualise surgery) ^[13] Senior notes: felixlai.md (Laryngeal carcinoma — RT complications: radiation dermatitis, hoarseness, dysphagia, odynophagia, laryngeal oedema, pharyngeal stenosis)

High Yield Summary

Definition: Malignant neoplasm of the oropharynx (tonsil, tongue base, soft palate, posterior pharyngeal wall); >90% SCC.

Epidemiology: Male predominance; bimodal age (younger HPV+, older HPV-); rising HPV-positive incidence globally.

Field cancerisation: Chronic carcinogen exposure → entire mucosa at risk → synchronous/metachronous tumours → always do panendoscopy (laryngoscopy + bronchoscopy + OGD).

Premalignant lesions: Erythroplakia (highest single-lesion malignant potential) > Speckled leukoplakia (highest transformation rate) > Leukoplakia.

AJCC 8th Edition: Separate staging for p16+ and p16- oropharyngeal SCC. HPV-positive tumours are "down-staged" reflecting better prognosis.

High Yield Summary

Differential Diagnosis of Oropharyngeal Masses — The Big Three:

SCC (~90%) — ulcerated, exophytic, risk factors (smoking/alcohol/HPV), p16 testing essential
Lymphoma — smooth, fleshy tonsillar/tongue base mass; tonsils and tongue base may be the presenting site for lymphoma; need tissue biopsy for subtyping
Minor salivary gland tumour — submucosal masses in tongue base and soft palate; smooth, intact mucosa

Infective mimics: Peritonsillar abscess (acute onset, fever, unilateral, trismus), deep neck space infection, TB pharyngitis

Neck mass differential: A cystic Level II mass in a patient > 40 = metastatic HPV+ oropharyngeal SCC until proven otherwise. Never call it a "branchial cleft cyst" without ruling out malignancy.

Key differentiating questions:

Acute vs chronic onset?
Unilateral vs bilateral?
Ulcerated surface vs smooth/submucosal?
Risk factors present?
B symptoms?

High Yield Summary

Diagnosis of oropharyngeal carcinoma requires histological confirmation — always biopsy.

Workup per lecture slides ^[4]:

History and Physical Examination (including flexible nasendoscopy)
Panendoscopy + biopsy — confirms histology; 10% risk of synchronous/metachronous tumour
Tonsillectomy or EUA + Bx — especially for occult tonsillar primary
Ultrasound neck +/- FNAC — FNA for cytology + p16/HPV testing on neck nodes
CXR — initial screen
CT / MRI — CT for bone and distant metastasis; MRI is the imaging modality of choice for oropharynx (soft tissue)
PET scan if necessary — for advanced disease, occult primary, distant metastasis

p16 IHC is the standard surrogate marker for HPV status. Positive = ≥ 70% diffuse nuclear + cytoplasmic staining → use AJCC 8th Ed HPV-positive staging.

CT vs MRI: CT better for cortical bone invasion; MRI better for soft tissue extent, marrow invasion, perineural spread. In practice, get BOTH.

FNA of nodes: Useful for cytology + HPV PCR; does NOT provide tissue architecture (cannot subtype lymphoma).

Panendoscopy = direct laryngoscopy + bronchoscopy + OGD: Mandatory for synchronous primary screening.

High Yield Summary

Management framework per lecture slides ^[8]:

Early stage (I, II) → single modality: surgery OR radiotherapy alone
Late stage (III, IV) → combined modality: concurrent CRT OR surgery + adjuvant RT ± chemo
General rule: Early = RT or minimally invasive surgery; Late = surgery + adjuvant
BUT: Oral cavity = surgery early; NPC = chemo-irradiation late
General principle: Tumour clearance + Organ/function preservation + Reconstruction for form and function + Rehabilitation always

Oropharynx-specific points ^[2]:

Oropharyngeal tumours are chemosensitive → CRT is a mainstay
TORS replaces the old lip-splitting mandibulotomy → shorter hospital stay, less morbidity
Adequate neck treatment is essential — 50% have nodal disease at presentation
CRT effectively preserves function with survival comparable to surgery + PORT

HPV-positive disease ^[2]:

Better prognosis, higher chemo-response, de-intensification being studied
Cetuximab + RT is NOT a valid de-intensification strategy (inferior to cisplatin + RT)
Cisplatin + RT remains the standard concurrent regimen

Adjuvant treatment after surgery ^[7]:

PORT indicated for: positive margins, PNI, LVI, ENE, advanced T stage
Add cisplatin to PORT if: positive margins or ENE

Metastatic/recurrent disease: Pembrolizumab ± platinum/5-FU (immunotherapy era)

Supportive care: Dental assessment pre-RT, nutritional support, swallowing rehabilitation, smoking cessation, airway protection — all mandatory.

Refer early: Persistent > 2–4 weeks, irregular, indurated, > 2 cm, cervical LN ^[11].

High Yield Summary

Radiotherapy complications:

Acute: mucositis (dose-limiting), radiation dermatitis, dysphagia/odynophagia, dysgeusia, early xerostomia
Late: chronic xerostomia, osteoradionecrosis (ORN) of mandible (prevention: pre-RT dental assessment), pharyngeal stenosis, hypothyroidism (screen TSH), carotid stenosis (stroke risk), late-RAD dysphagia, radiation-induced second malignancy

Chemotherapy complications: Cisplatin → nephrotoxicity, ototoxicity, nausea/vomiting, myelosuppression, peripheral neuropathy, additive mucositis with RT.

Immunotherapy complications: irAEs — pneumonitis, colitis, hepatitis, thyroiditis; manage with steroids.

Rehabilitation always — swallowing, voice and hearing ^[8].

Oropharyngeal Carcinoma

Oropharyngeal Carcinoma

2. Epidemiology

3. Anatomy and Function

4. Etiology and Risk Factors

4.2 Human Papillomavirus (HPV) Infection

The "5 S's" Mnemonic for Oral/Oropharyngeal Cancer Risk Factors:

5. Pathophysiology

5.5 Patterns of Metastasis

6. Classification

7. Clinical Features

Active Recall - Oropharyngeal Carcinoma (Definition to Clinical Features)

Differential Diagnosis of Oropharyngeal Masses / Lesions

Structured Differential Diagnosis

Active Recall - Differential Diagnosis of Oropharyngeal Carcinoma

References

Diagnostic Criteria, Algorithm and Investigations for Oropharyngeal Carcinoma

3. Investigation Modalities — Detailed Breakdown

3.3 Pathological Tests on Biopsy/FNA Specimens

3.4 Imaging Investigations

Active Recall - Diagnosis and Investigations of Oropharyngeal Carcinoma

References

Management of Oropharyngeal Carcinoma

3. Treatment Modalities — Detailed Breakdown

3.1 Surgery

3.2 Radiotherapy (RT)

3.3 Chemotherapy

3.5 Specific Management by Stage

Active Recall - Management of Oropharyngeal Carcinoma

References

Complications of Oropharyngeal Carcinoma

1. Complications of the Disease Itself (Untreated or Progressive Tumour)

2. Complications of Treatment

2.1 Complications of Surgery

2.2 Complications of Radiotherapy

Active Recall - Complications of Oropharyngeal Carcinoma

References

On this page

Oropharyngeal Carcinoma

1. Definition

2. Epidemiology

2.1 General Epidemiology

2.2 Global Trends

2.3 Hong Kong Context

3. Anatomy and Function

3.1 Boundaries of the Oropharynx

3.2 Sub-sites of the Oropharynx

3.3 Key Adjacent Structures and Spaces

3.4 Lymphatic Drainage

3.5 Nerve Supply (Relevant to Symptoms)

3.6 Function of the Oropharynx

4. Etiology and Risk Factors

4.1 Overview — The "Big Four" for Head and Neck Cancer

4.2 Human Papillomavirus (HPV) Infection

Pathophysiology of HPV-driven carcinogenesis:

Clinical and Demographic Features of HPV-Positive Oropharyngeal SCC:

4.3 Smoking

4.4 Alcohol

4.5 Epstein-Barr Virus (EBV)

4.6 Other Risk Factors

5. Pathophysiology

5.1 Field Cancerisation

5.2 Premalignant Lesions

5.3 Molecular Pathogenesis

5.4 Patterns of Local Spread

5.5 Patterns of Metastasis

Lymph Node Metastasis:

Distant Metastasis:

6. Classification

6.1 Histological Classification

6.2 WHO Classification of Head and Neck SCC (Histological Subtypes)

6.3 HPV Status Classification (AJCC 8th Edition, Current Standard)

6.4 TNM Staging — Key Differences

7. Clinical Features

7.1 Symptoms

7.2 Signs

7.3 Clinical Presentation by Sub-site

8. Differential Diagnosis (Brief Overview — to be expanded later)

Active Recall - Oropharyngeal Carcinoma (Definition to Clinical Features)

References

Guiding Principle: What Tissues Live in the Oropharynx?

Structured Differential Diagnosis

A. Malignant Causes (Must-Exclude Differentials)

B. Benign Neoplasms

C. Infective and Inflammatory Conditions

D. Premalignant Conditions

E. Other Conditions Presenting as a Neck Mass (When Cervical Lymphadenopathy Is the Presenting Feature)

Clinical Approach: How to Differentiate — A Diagnostic Thinking Framework

Key Differentiating Principles — Summary Table

Why Each Differential Matters — Reasoning from First Principles

Active Recall - Differential Diagnosis of Oropharyngeal Carcinoma

1. Diagnostic Criteria — How Do We Confirm Oropharyngeal Carcinoma?

2. Diagnostic Algorithm

3. Investigation Modalities — Detailed Breakdown

3.1 History and Physical Examination

3.2 Panendoscopy + Biopsy — The Definitive Diagnostic Procedure

3.3 Pathological Tests on Biopsy/FNA Specimens

a) Histopathology

b) p16 Immunohistochemistry (IHC) — Surrogate Marker for HPV

c) HPV-Specific Testing (When Needed)

d) FNA of Cervical Lymph Nodes

3.4 Imaging Investigations

a) Ultrasound (USG) of the Neck

b) CT Scan (Computed Tomography)

c) MRI Scan (Magnetic Resonance Imaging)

d) PET-CT Scan (Positron Emission Tomography – Computed Tomography)

e) CXR (Chest X-Ray)

3.5 Blood Tests and Biomarkers

3.6 Pre-Treatment Assessment — Multidisciplinary

4. Interpretation Framework — Putting It All Together

Active Recall - Diagnosis and Investigations of Oropharyngeal Carcinoma

1. General Principles of Management

2. Management Algorithm

3. Treatment Modalities — Detailed Breakdown

3.1 Surgery

a) Transoral Robotic Surgery (TORS)

b) Open Surgery

c) Neck Dissection